TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30563215

Group type: EXPERIMENTAL
Intervention: Daily administration of vitamin D (7 drops, 1750 IU/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monthly administration of vitamin D (50,000 IU/month)
Number of subjects: 44
Study: 27569936

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Everolimus (TAC/EVL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tacrolimus/Enteric-Coated Mycophenolate Sodium (TAC/EC-MPS)
Number of subjects: 30
Study: 24982088

Group type: EXPERIMENTAL
Intervention: VX-222 (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VX-222 and telaprevir (dual combination therapy) for 12 weeks
Number of subjects: 0
Study: 22439742

Group type: EXPERIMENTAL
Intervention: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) followed by 2 years of adjuvant hormone therapy (HT) with luteinizing hormone-releasing hormone agonist.
Number of subjects: 340

Group type: COMPARATOR
Intervention: Trimodality therapy including iodine-125 brachytherapy (125I-BT), external beam radiation therapy (EBRT), and 6-month combined androgen blockade (CAB) without long-term hormone therapy.
Number of subjects: 340
Study: 20536522

Group type: EXPERIMENTAL
Intervention: Nutritional Education Programme (group A)
Number of subjects: 256
Study: 18432175

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 0
Study: 16102379

Group type: EXPERIMENTAL
Intervention: AUDIT1 (original version starting with three items addressing frequency and quantity of alcohol use)
Number of subjects: 10803

Group type: COMPARATOR
Intervention: AUDIT2 (version with items addressing frequency and quantity of alcohol use at the end)
Number of subjects: 10803
Study: 11828745

Group type: EXPERIMENTAL
Intervention: Corticosteroid creams (Lidomex) alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Admixture of Lidomex ointment and urea/heparinoid ointments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ointments alone
Number of subjects: 20
Study: 9988786

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 116
Study: 7760608

Group type: EXPERIMENTAL
Intervention: 30% oxygen in nitrogen during anaesthesia induction
Number of subjects: 12

Group type: COMPARATOR
Intervention: 100% oxygen during induction and 40% oxygen in nitrogen thereafter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30% oxygen (subgroup A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100% oxygen (subgroup B)
Number of subjects: 12
Study: 2182205

Group type: EXPERIMENTAL
Intervention: Lidocaine CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two per cent lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two per cent lidocaine with pH adjusted by bicarbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three solutions
Number of subjects: 0
Study: 6111126

Group type: EXPERIMENTAL
Intervention: Triazolam (Halcion) 0.25 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (Rohypnol) 2 mg
Number of subjects: 55
Study: 31709697

Group type: EXPERIMENTAL
Intervention: Food-based, low-energy, low-carbohydrate diet (800-1000 kcal/day, <26% energy) for 8 weeks with behavioral support
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 33
Study: 29306491

Group type: EXPERIMENTAL
Intervention: Embryo flash located <15 mm from the fundus
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Embryo flash located >15 mm from the fundus
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Embryo flash movement/migration at 60 minutes after ET
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Fundal position of embryo flash
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Static position of embryo flash
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Cervical position of embryo flash
Number of subjects: 230
Study: 27546774

Group type: COMPARATOR
Intervention: Critical care outreach delivered by a team of intensive care nurses implemented across general hospital wards.
Number of subjects: 18682
Study: 25081360

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 286
Study: 22915639

Group type: EXPERIMENTAL
Intervention: Recombinant gp120 vaccination
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1725
Study: 21081600

Group type: EXPERIMENTAL
Intervention: Reviewer's signed report made available on the BMJ's website alongside the published paper (intervention group)
Number of subjects: 471

Group type: COMPARATOR
Intervention: BMJ's normal procedure (control group)
Number of subjects: 471
Study: 18757088

Group type: EXPERIMENTAL
Intervention: Ivabradine (5 mg, with intention to increase to 7.5 mg twice a day)
Number of subjects: 10917

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study: 15750103

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once daily for a mean duration of 27 days (SD 12.2 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo once daily for a mean duration of 27 days (SD 13.9 days)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Clarithromycin and Placebo
Number of subjects: 76
Study: 12651918

Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site B
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Site C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control site (Site A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-dose sodium nitroprusside (SNP) infusion during hyperthermia at Sites B and C
Number of subjects: 8
Study: 10961763

Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride (10% solution, 1 ml, 40-50 mg per application)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lidocaine (10% solution, 1 ml)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study: 8856622

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 21

Group type: COMPARATOR
Intervention: paracetamol
Number of subjects: 21
Study: 1630740

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 0
Study: 6377866

Group type: COMPARATOR
Intervention: Fluorouracil (FU) alone
Number of subjects: 207

Group type: COMPARATOR
Intervention: Fluorouracil (FU) + hydroxyurea (HU)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Semustine (SE) + dacarbazine (DA)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) + hydroxyurea (HU) alternating with semustine (SE) + dacarbazine (DA)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Semustine (SE) + razoxane (RA)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Mitomycin (MI) + dacarbazine (DA)
Number of subjects: 207
Study: 31775699

Group type: EXPERIMENTAL
Intervention: Vlog unboxing fruit and vegetables (preparing and tasting)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Vlog doing a challenge with fruit and vegetables (e.g., contests, tricks, games)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 350
Study: 29373294

Group type: EXPERIMENTAL
Intervention: povidone-iodine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: povidone-iodine with a drape
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: chlorhexidine-alcohol
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: chlorhexidine-alcohol with a drape
Number of subjects: 126
Study: 26618547

Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1108
Study: 26253734

Group type: COMPARATOR
Intervention: Lead shield
Number of subjects: 230

Group type: COMPARATOR
Intervention: Surgical cap
Number of subjects: 230
Study: 22683252

Group type: EXPERIMENTAL
Intervention: PF 1 mg + ranibizumab (combination) Q4W
Number of subjects: 151

Group type: COMPARATOR
Intervention: ranibizumab Q4W
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: PF 1 mg every 4 weeks (Q4W)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: PF 3 mg Q4W
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: PF 3 mg every 2 weeks (Q2W)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: PF monotherapy groups
Number of subjects: 151
Study: 20236984

Group type: EXPERIMENTAL
Intervention: Theory-based, multi-level intervention
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Standard health curriculum (Control)
Number of subjects: 2343
Study: 18523642

Group type: EXPERIMENTAL
Intervention: Home based intervention for caregivers, including information on dementia, guidance on behaviour management, psychiatric assessment, and psychotropic medication if needed.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Waiting list control group (received intervention after 6 months)
Number of subjects: 81
Study: 15777680

Group type: EXPERIMENTAL
Intervention: Riboflavin intake
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Low riboflavin, B12, B6, and folate intake
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1700
Study: 11994976

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) alone (15, 45, or 75 mg/m²/day on alternate days for 21 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tamoxifen (Tam) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) + Tamoxifen (Tam)
Number of subjects: 30
Study: 10348498

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) diet on day 7
Number of subjects: 12

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) diet on day 7
Number of subjects: 12
Study: 8948338

Group type: EXPERIMENTAL
Intervention: 45 Gy in 5 weeks
Number of subjects: 379

Group type: COMPARATOR
Intervention: 59.4 Gy in 6.6 weeks
Number of subjects: 379
Study: 1816813

Group type: EXPERIMENTAL
Intervention: 2% epinephrine-free Articain solution (Ultracain 2%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4% Articain solution with epinephrine (Ultracain D-S)
Number of subjects: 0
Study: 6095602

Group type: EXPERIMENTAL
Intervention: Misonidazole (radiosensitizer)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Chemotherapy (bleomycin, methotrexate, vincristine) before irradiation
Number of subjects: 410
Study: 31622159

Group type: EXPERIMENTAL
Intervention: Potato purée ingestion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Carbohydrate gel ingestion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water condition
Number of subjects: 12
Study: 29893297

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (with or without pioglitazone)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 16
Study: 27989278

Group type: EXPERIMENTAL
Intervention: Stress management intervention, relaxation, physical exercise and moor applications (3-week program)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waiting control group (WG)
Number of subjects: 88
Study: 24509026

Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 930
Study: 19803574

Group type: EXPERIMENTAL
Intervention: Brief motivational treatment (telephone motivational interview and mailed self-help workbook)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Brief motivational booster treatment (telephone motivational interview, workbook, and 6 booster calls over 9 months)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Workbook only control
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Brief booster treatment
Number of subjects: 314
Study: 15712819

Group type: EXPERIMENTAL
Intervention: Culturally Appropriate Breast Educational Intervention Program (CABHEIP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Attention control group (education on poison control)
Number of subjects: 120
Study: 11680565

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Detox-only
Number of subjects: 105
Study: 9414143

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theophylline (200 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7969599

Group type: EXPERIMENTAL
Intervention: Waking advice (WA) given to non-professional caregivers of MHI patients, with a waking interval of 1-4 hours.
Number of subjects: 326
Study: 3670868

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Distraction with suggestion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Suggestion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 30770308

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide with dose reductions
Number of subjects: 0
Study: 29936419

Group type: EXPERIMENTAL
Intervention: Golf training (24-week, 90-120 min sessions/week)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 106
Study: 27402596

Group type: EXPERIMENTAL
Intervention: Acute administration of ghrelin
Number of subjects: 21
Study: 25127084

Group type: EXPERIMENTAL
Intervention: Restorative yoga
Number of subjects: 171

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 171
Study: 22432824

Group type: EXPERIMENTAL
Intervention: Intraligamentary injection of piroxicam (0.4 mL)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo group (intraligamentary injection of lidocaine, 0.4 mL)
Number of subjects: 65
Study: 19158153

Group type: EXPERIMENTAL
Intervention: Treatment by female physicians
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Treatment by male physicians
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Female patients
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Female gender of physicians
Number of subjects: 1857
Study: 17192771

Group type: EXPERIMENTAL
Intervention: 1,4-butanediol (BD) 25 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15114226

Group type: EXPERIMENTAL
Intervention: Intravenous pentazocine (0.5 mg/kg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 79
Study: 11404446

Group type: EXPERIMENTAL
Intervention: Diabetic employees
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-diabetic employees
Number of subjects: 400
Study: 9779697

Group type: EXPERIMENTAL
Intervention: 200 microg OTFC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 400 microg OTFC
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: OTFC (dose-titrated)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual breakthrough medication
Number of subjects: 62
Study: 7843102

Group type: EXPERIMENTAL
Intervention: High exposure to Cd and Ni
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low exposure to Cd and Ni
Number of subjects: 12

Group type: COMPARATOR
Intervention: Light exposure to Cd (< 100 micrograms/m3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heavy exposure to Cd (> 200 micrograms/m3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Light exposure to Ni (< 100 micrograms/m3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heavy exposure to Ni (> 200 micrograms/m3)
Number of subjects: 12
Study: 3339482

Group type: EXPERIMENTAL
Intervention: Intensive education program for internal medicine residents
Number of subjects: 45
Study: 31325350

Group type: EXPERIMENTAL
Intervention: Dietary habits (eating rice at least three times per week or eating fish at least once per week)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Antecedent infections
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (partners of patients with CIDP)
Number of subjects: 323
Study: 27334234

Group type: EXPERIMENTAL
Intervention: 30% rebate on targeted fruits and vegetables (TFVs) purchased with SNAP benefits
Number of subjects: 7500

Group type: COMPARATOR
Intervention: Usual SNAP benefits
Number of subjects: 7500
Study: 25644275

Group type: EXPERIMENTAL
Intervention: D-Stat (collagen and thrombin mixture)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Vacuum drainage
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: D-Stat
Number of subjects: 164
Study: 23241989

Group type: EXPERIMENTAL
Intervention: DTaP₅‐IPV‐Hib‐HepB plus PCV7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP₅‐IPV‐Hib‐HepB with PCV7 administered 1 month later
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTaP₅‐IPV/Hib plus HepB plus PCV7
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21098340

Group type: EXPERIMENTAL
Intervention: 6-month multitask exercise program performed to the rhythm of piano music
Number of subjects: 134

Group type: COMPARATOR
Intervention: Delayed intervention control group (scheduled to start the program 6 months later)
Number of subjects: 134
Study: 17483245

Group type: EXPERIMENTAL
Intervention: Cyclin E levels in tumours with an infiltrative growth pattern (n = 141)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cyclin E levels in tumours with a pushing margin phenotype
Number of subjects: 187

Group type: COMPARATOR
Intervention: Tamoxifen treatment
Number of subjects: 187
Study: 17038140

Group type: EXPERIMENTAL
Intervention: Atrioventricular junction (AVJ) ablation followed by biventricular pacing
Number of subjects: 180

Group type: COMPARATOR
Intervention: Pharmacologic rate control
Number of subjects: 180
Study: 12868995

Group type: EXPERIMENTAL
Intervention: Basiliximab plus early low-dose cyclosporin
Number of subjects: 100

Group type: COMPARATOR
Intervention: OKT3 induction therapy
Number of subjects: 100
Study: 10720881

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/day for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9188207

Group type: EXPERIMENTAL
Intervention: Bamiphylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1447432

Group type: EXPERIMENTAL
Intervention: clomipramine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: lofepramine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (age and sex matched)
Number of subjects: 66
Study: 4078175

Group type: EXPERIMENTAL
Intervention: Frequency increments
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Frequency decrements
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intensity increments
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intensity decrements
Number of subjects: 32
Study: 31630589

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, fentanyl, and propofol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Fentanyl and propofol
Number of subjects: 114
Study: 29068321

Group type: EXPERIMENTAL
Intervention: Asthma group (atopic and non-atopic)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Atopic asthma group
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Non-atopic asthma group
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (subjects without asthma)
Number of subjects: 314
Study: 26686695

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) in women
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) in men
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (non-DM) in women
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (non-DM) in men
Number of subjects: 332
Study: 24239513

Group type: EXPERIMENTAL
Intervention: NEAT Girls obesity prevention program
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 330
Study: 22199136

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) with good adherence (≥ 4h/night)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Adaptive servo-ventilation (ASV) with poor adherence (<4h/night)
Number of subjects: 85
Study: 20182403

Group type: EXPERIMENTAL
Intervention: Intravitreal injection (IVT) of 4 mg triamcinolone acetonide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subtenon infusion (STI) of 40 mg triamcinolone acetonide
Number of subjects: 24
Study: 17492909

Group type: EXPERIMENTAL
Intervention: Psychiatric advance directives (PADs)
Number of subjects: 28
Study: 16264062

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 400 mug once daily in the evening
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF-DPI) 200 mug twice daily
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 12131245

Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Back-pain patients
Number of subjects: 43
Study: 10223933

Group type: EXPERIMENTAL
Intervention: SB 209763 (10 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SB 209763 (various doses: 0.25, 1.25, 5.0, or 10.0 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SB 209763 (1.25 to 10.0 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SB 209763
Number of subjects: 43
Study: 7829790

Group type: EXPERIMENTAL
Intervention: tissue-type plasminogen activator (t-PA)
Number of subjects: 395

Group type: COMPARATOR
Intervention: primary angioplasty
Number of subjects: 395
Study: 2398130

Group type: EXPERIMENTAL
Intervention: Coe-pak
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Wondrpak
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Nobetec
Number of subjects: 226